​

Alterity Therapeutics (ATHE) Stock Forecast, Price Target & Predictions

OverviewChart

ATHE Stock Rating

Alterity Therapeutics stock's rating consensus is Buy, based on 8 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (50.00%), 4 Hold (50.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 8 0 4 4 Strong Sell Sell Hold Buy Strong Buy

ATHE Price Target Upside V Benchmarks

TypeNameUpside
StockAlterity Therapeutics-
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$4.76$4.76$4.76
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 2511---2
Sep, 25111--3
Aug, 25111--3
Jul, 25111--3
Jun, 25111--3
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Feb 03, 2025BenchmarkSpeculative BuyBuydowngrade
Sep 26, 2022BenchmarkSpeculative BuySpeculative Buyhold

Financial Forecast

EPS Forecast

$-6 $-5 $-4 $-3 $-2 $-1 $0 Jun 21 Jun 22 Jun 23 Jun 24 Jun 25 Jun 26 Jun 27 Jun 28 Jun 29
Jun 21Jun 22Jun 23Jun 24Jun 25Jun 26Jun 27Jun 28Jun 29
Reported$-5.41$-3.20-------
Avg Forecast$-3.58$-3.04$-1.20$-1.66$-0.88$-0.66$-0.61$-1.02$-1.09
High Forecast$-3.58$-3.04$-1.20$-1.66$-0.88-$-0.61$-1.02$-1.09
Low Forecast$-3.58$-3.04$-1.20$-1.66$-0.88$-1.32$-0.61$-1.02$-1.09
Surprise %51.12%5.26%-------

Revenue Forecast

$2M $2M $3M $4M $5M $6M Jun 21 Jun 22 Jun 23 Jun 24 Jun 25 Jun 26 Jun 27 Jun 28 Jun 29
Jun 21Jun 22Jun 23Jun 24Jun 25Jun 26Jun 27Jun 28Jun 29
Reported$3.25M$3.54M-------
Avg Forecast$2.77M$3.10M$3.04M$2.58M$5.07M$2.94M$1.81M$3.91M$3.88M
High Forecast$2.77M$3.10M$3.04M$2.58M$5.07M$3.07M$1.81M$3.91M$3.88M
Low Forecast$2.77M$3.10M$3.04M$2.58M$5.07M$2.81M$1.81M$3.91M$3.88M
Surprise %17.49%14.16%-------

Net Income Forecast

$-25B $-20B $-15B $-10B $-5B $0 Jun 21 Jun 22 Jun 23 Jun 24 Jun 25 Jun 26 Jun 27 Jun 28 Jun 29
Jun 21Jun 22Jun 23Jun 24Jun 25Jun 26Jun 27Jun 28Jun 29
Reported$-15.31M$-12.85M$-13.81M------
Avg Forecast$-21.76B$-18.51B$-4.36B$-6.04B$-3.20B$-2.41B$-2.23B$-3.72B$-3.98B
High Forecast$-21.76B$-18.51B$-4.36B$-6.04B$-3.20B$-8.04M$-2.23B$-3.72B$-3.98B
Low Forecast$-21.76B$-18.51B$-4.36B$-6.04B$-3.20B$-4.81B$-2.23B$-3.72B$-3.98B
Surprise %-99.93%-99.93%-99.68%------

ATHE Forecast FAQ

Is Alterity Therapeutics stock a buy?

Alterity Therapeutics stock has a consensus rating of Buy, based on 8 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 4 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Alterity Therapeutics is a favorable investment for most analysts.

What is Alterity Therapeutics's price target?

Alterity Therapeutics's price target, set by 8 Wall Street analysts, averages - over the next 12 months. The price target range spans from - at the low end to - at the high end, suggesting a potential 0% change from the previous closing price of $4.76.

How does Alterity Therapeutics stock forecast compare to its benchmarks?

Alterity Therapeutics's stock forecast shows a 0% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Alterity Therapeutics over the past three months?

  • October 2025: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 33.33% Strong Buy, 33.33% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 33.33% Strong Buy, 33.33% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.

What is Alterity Therapeutics’s EPS forecast?

Alterity Therapeutics's average annual EPS forecast for its fiscal year ending in June 2024 is $-1.66, marking a 0% decrease from the reported $0 in 2023. Estimates for the following years are $-0.88 in 2025, $-0.66 in 2026, $-0.61 in 2027, $-1.02 in 2028, and $-1.09 in 2029.

What is Alterity Therapeutics’s revenue forecast?

Alterity Therapeutics's average annual revenue forecast for its fiscal year ending in June 2024 is $2.58M, reflecting a 0% decrease from the reported $0 in 2023. The forecast for 2025 is $5.07M, followed by $2.94M for 2026, $1.81M for 2027, $3.91M for 2028, and $3.88M for 2029.

What is Alterity Therapeutics’s net income forecast?

Alterity Therapeutics's net income forecast for the fiscal year ending in June 2024 stands at $-6.043B, representing an 43669.02% increase from the reported $-13.807M in 2023. Projections indicate $-3.199B in 2025, $-2.409B in 2026, $-2.234B in 2027, $-3.722B in 2028, and $-3.977B in 2029.